Kaiseraugst (Switzerland), Heerlen (The Netherlands), June 25, 2024
dsm-firmenich, innovators in nutrition, health, and beauty, has announced the launch of CBtru® – an advanced formulated cannabidiol (CBD) drug product intermediate designed for oral solid delivery formats. The IP-protected CBD intermediate brings superior functionality allowing for a higher drug loading compared to currently commercially available products, paving the way for oral dosage forms with enhanced bioavailability. This will enable the development of more convenient and patient-friendly dosage forms – like tablets, including orally disintegrating tablets (ODTs) or chewables - making CBtru® a remarkable advancement in cannabinoid innovation with the capacity to transform CBD-based therapies.
Pioneering a new frontier in CBD drug development
Existing CBD-based medicines exhibit limited oral bioavailability (as low as 6% in humans), and therefore efficacy, due to the poor solubility and absorption of cannabinoid molecules.1 Consequently, large doses of CBD are needed for therapeutic effectiveness and require administration via oil-based oral solutions, which can be inconvenient and unpleasant for patients to ingest. dsm-firmenich’s cutting-edge formulated CBD drug product intermediate aims to address this challenge. It allows for higher active loading, improved stability and optimized pharmacokinetic performance, enabling the creation of more bioavailable and patient-friendly dosage forms.
“We’re committed to elevating global patient health by unlocking new treatment possibilities and improving product acceptance and compliance. That’s why we have invested in CBD – a molecule that holds immense therapeutic potential, as evidenced by promising research and a shifting favorable regulatory environment,” remarks Athanasia Kanli, Global Business Development Manager for Pharma at dsm-firmenich. “To date, the application of CBD has been limited to oil-based delivery systems though, principally because of its low bioavailability and physical and chemical instability. This inspired us to introduce CBtru® to the rapidly expanding cannabinoid market. With its advanced functionality, CBtru® can facilitate the development of faster-acting, more effective and patient-friendly treatments – representing a new era in cannabinoid-based medicines.”
dsm-firmenich’s novel CBD drug product intermediate is the result of two years of focused research. During this period, the company’s technical team rigorously assessed more than 200 prototypes and multiple drug delivery technologies to identify a CBD solution with superior performance. Moving forward, dsm-firmenich is eager to establish long-term strategic partnerships to investigate new therapeutic applications leveraging its trial-ready CBtru® formulation.
More than CBtru®
Together with Brains Bioceutical – manufacturer of high-quality pharma-grade cannabinoids – dsm-firmenich offers an end-to-end innovation platform designed to support early-stage cannabinoid drug development and realize the potential of CBD-based formulations. Its capabilities include leading-edge formulation expertise, a global network of regulatory specialists and preclinical and clinical study proficiency. The company also has the capacity to provide customized solutions depending on the therapeutic area and drug delivery objective.
To learn more about how dsm-firmenich’s cannabinoid innovation platform is helping to elevate patient health, visit our website.
About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life™ every day, everywhere, for billions of people. www.dsm-firmenich.com
Céline Zuber
Global Marketing Communications Manager
Matilde Martinuzzi
Senior PR Account Executive, Barret Dixon Bell
dsm-firmenich
Forward-looking statements
This press release may contain forward-looking statements with respect to dsm-firmenich’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. The English language version of this press release prevails over other language versions.
